Vaccine Research

About Conference

Welcome to the 6th International Conference on Vaccine Research — Paris, 2025

We are delighted to welcome you to the 6th International Conference on Vaccine Research, held on November 19–20, 2025, in Tokyo, Japan. This premier global event unites leading vaccine researchers, immunologists, public health experts, and industry innovators under the unifying theme, “Unifying Science for a Health-Secure Future.”

Join us as we explore groundbreaking advancements in vaccine development, immunization strategies, and infectious disease prevention. The conference agenda features expert-led sessions on novel vaccine technologies, global vaccination programs, pandemic preparedness, and equitable access to immunization worldwide.

This is your opportunity to connect with top scientists, policymakers, and healthcare professionals dedicated to advancing vaccinology and strengthening global health security. Collaborate on innovative solutions that address emerging health threats and help build a resilient, disease-free future.

Register today to be part of this dynamic forum driving the future of vaccine research and public health innovation.

Scope & Importance

Why Attend the 6th International Conference on Vaccine Research?

The 6th International Conference on Vaccine Research, themed “Unifying Science for a Health-Secure Future”, is a premier global forum dedicated to advancing vaccine science and public health.

Key Reasons to Attend:

• Discover Cutting-Edge Research: Engage with the latest advancements in vaccine development, immunization strategies, and infectious disease prevention.
• Network with Global Experts: Connect with leading scientists, clinicians, policymakers, and industry professionals from around the world.
• Enhance Professional Skills: Participate in workshops and sessions designed to deepen your understanding of vaccinology and its applications.
• Contribute to Global Health: Collaborate on initiatives aimed at achieving equitable access to vaccines and strengthening health systems worldwide.

Target Audience:

This conference is designed for:

• Vaccine Researchers and Developers
• Immunologists and Microbiologists
• Public Health Officials and Policymakers
• Healthcare Providers and Clinicians
• Pharmaceutical and Biotech Industry Leaders
• Academic Scholars and Students
• Regulatory and Compliance Professionals
• Non-Governmental Organizations (NGOs) and Health Advocates

Sessions/Tracks

Track 1: Next-Generation Vaccine Technologies

As the global demand for faster, safer, and more effective vaccine development, including mRNA, DNA, and viral vector platforms. cutting-edge technologies are shaping the future of immunization. This session will delve into the revolutionary advancements in vaccine development platforms, with a special focus on mRNA vaccines, DNA-based vaccines, viral vectors, nanoparticle-based delivery systems and immunization strategies.

• mRNA and DNA vaccines    
• Nanoparticle-based delivery                         
• Bioinformatics in vaccine design                             
• Reverse vaccinology                         
• TLR agonists

Track 2: Vaccine Safety and Pharmacovigilance

Vaccine safety and pharmacovigilance play a crucial role in ensuring that vaccines are both effective and safe for public use. This involves continuous monitoring of adverse effects, risk-benefit analysis, and implementation of preventive measures throughout the vaccine development and distribution process. One of the fundamental aspects of this field is  clinical trial safety, which ensures that all vaccine candidates undergo rigorous safety assessments during each phase of clinical trials before approval. 

• Adverse event monitoring                            
• Risk-benefit assessment                                            
• Global safety reporting                                 
• Post-marketing surveillance

Track 3: Global Immunization Programs and Policy

Global immunization programs play a pivotal role in reducing the burden of infectious diseases worldwide. Through coordinated policy efforts by organizations like the World Health Organization (WHO), GAVI, and various national health agencies, vaccines have become a cornerstone of public health. A key focus of these programs is vaccine accessibility ensuring that individuals—regardless of geography, income, or social status—can receive life-saving immunizations.

• Vaccine equity                                  
• National immunization schedules                             
• GAVI & COVAX initiatives                        
• Public health advocacy

Track 4: Pediatric and Neonatal Vaccines

Pediatric and Neonatal Vaccines play a crucial role in protecting infants and young children from life-threatening infectious diseases during their most vulnerable stages. These vaccines are carefully designed based on the principles of pediatric immunology which studies the unique characteristics and responses of the developing immune system in children. Immunizing neonates and infants not only provides immediate protection against common pathogens but also contributes to long-term immunity and overall public health.

• Live-attenuated vs inactivated vaccines                               
• Neonatal immunity                           
• Age-specific formulation                              
• School immunization strategies

Track 5: Adult and Elderly Vaccination Strategies

Vaccination plays a vital role in safeguarding the health of adults and the elderly, especially those managing chronic conditions. As the immune system naturally weakens with age, individuals in geriatrics are more susceptible to infectious diseases such as influenza, pneumonia, and shingles. Strategic vaccination programs targeted toward this population not only help prevent illness but also reduce the risk of complications in those with existing chronic health issues like diabetes, heart disease, and respiratory disorders

• Adult booster schedules                               
• Geriatric immunology                       
• Workplace vaccine programs                        
• Immune response in aging

Track 6: Cancer Vaccines and Immunotherapy

Cancer vaccines, and immunotherapy represent a transformative frontier in oncology, harnessing the immune system to detect and destroy malignant cells. Cancer vaccines, including preventive and therapeutic types, are being developed to target tumor-specific antigens. Neoantigen -based strategies offer personalized approaches by identifying unique mutations in a patient’s tumor to stimulate a precise immune response. Combining vaccines with checkpoint inhibitors and adoptive cell therapies is enhancing treatment efficacy. Ongoing research aims to improve delivery, reduce resistance, and broaden application across cancer types.

• HPV and cervical cancer                              
• Lung, melanoma & prostate vaccines                       
• Immunomodulators                           
• Tumor microenvironment research

Track 7: Infectious Disease Vaccines

Infectious Disease Vaccines play a vital role in controlling global health threats by preventing the spread of deadly pathogens. Significant advances have been made in vaccines targeting Influenza, which continues to evolve and cause seasonal outbreaks. Efforts are ongoing to develop more effective vaccines for Tuberculosis (TB), a major global killer. Zika and Dengue viruses, transmitted by mosquitoes, pose growing public health risks in tropical regions, prompting the development of new generation vaccines. This track will explore current challenges, clinical trials, and breakthroughs in vaccines for these and other infectious diseases.

• COVID-19                            
• HIV/AIDS                            
• Influenza & RSV                              
• Vector-borne diseases

Track 8: COVID-19 Vaccine Impact and Learnings

The COVID-19 pandemic triggered an unprecedented global effort to develop, distribute, and administer vaccines at record speed. These vaccines played a critical role in reducing severe illness, hospitalizations, and death rates across populations. The experience revealed both the power of scientific collaboration and the challenges of equitable access, vaccine hesitancy, and misinformation. It also highlighted the importance of strong healthcare infrastructure and global preparedness for future pandemics. Lessons learned from COVID-19 vaccine deployment are now guiding strategies for emerging infectious diseases worldwide.

• Vaccine rollout impact                                 
• Variants and vaccine response                                  
•  Public trust building                          
• Global policy response

Track 9: Veterinary and Zoonotic Vaccines

Veterinary and zoonotic vaccines play a crucial role in preventing disease transmission between animals and humans, especially in the context of emerging infectious diseases. As over 60% of human pathogens are zoonotic, developing effective animal vaccines is vital for global health security. These vaccines help control outbreaks at their source, reduce economic losses in livestock, and protect food systems. Innovations in veterinary immunology and cross-species vaccine development are transforming One Health strategies. Strengthening global collaboration in zoonotic vaccine research is essential for pandemic preparedness and public health resilience.

• Animal vaccine R&D                       
• Rabies, brucellosis, anthrax                          
• One Health approach                        
• Cross-species immunity

Track 10: AI and Data Science in Vaccine Discovery

AI and big data analytics are transforming vaccine discovery by accelerating antigen identification, epitope mapping, and immune response prediction. Machine learning algorithms analyze vast datasets from genomics, proteomics, and epidemiology to identify promising vaccine targets with greater speed and precision. AI models can simulate virus-host interactions and optimize vaccine formulations before entering clinical trials. Big data enables real-time monitoring of pathogen evolution and vaccine efficacy across populations. This synergy of AI and data science is paving the way for faster, cost-effective, and more personalized vaccine development.

• Machine learning in immunogen prediction                        
• Clinical trial automation                               
• Digital health records for trials                                 
• Predictive modeling in vaccine efficacy

Track 11: Manufacturing, Supply Chain, and Distribution

This track explores the critical role of manufacturing infrastructure, cold-chain logistics, and equitable distribution strategies in ensuring timely and effective vaccine delivery worldwide. Experts will discuss innovations in scalable vaccine production, supply chain resilience during pandemics, and public-private partnerships that enable access in low-resource settings. Emphasis will be placed on digital tracking systems, regulatory harmonization, and last-mile delivery solutions. Case studies from global COVID-19 vaccination efforts will highlight lessons learned and future preparedness. Ensuring consistent global vaccine delivery  remains essential for disease control and health equity.

• GMP compliance                              
• Cold storage logistics                        
• Bulk production technologies                       
• Regional vaccine hubs

Track 12: Vaccine Research Ethics and Regulations

Vaccine Research Ethics and Regulations focus on safeguarding participants and maintaining integrity throughout the process of vaccine development. Ethical considerations are essential for ensuring transparency, informed consent, and equitable access during vaccine trials. Regulatory frameworks play a pivotal role in maintaining global standards and public trust. As the landscape evolves,  research recognition becomes crucial in acknowledging ethically conducted and impactful studies. This track highlights the intersection of ethics, governance, and innovation in advancing safe and effective vaccines.

• Global regulatory frameworks
• Ethics in pediatric trials
• Community consent models
• Transparency in research

Track 13: Antimicrobial Resistance and Vaccines

The global rise in antimicrobial resistance (AMR) poses a serious threat to public health, largely driven by excessive and inappropriate antibiotic usage. Vaccines play a critical role in combating antimicrobial resistance by preventing infections and reducing the need for antibiotics. By lowering disease incidence, vaccines help minimize antibiotic exposure and slow the evolution of resistant strains. Integrating vaccination into AMR strategies can significantly curb the spread of resistant pathogens. This track will explore vaccine development, policy integration, and global efforts to address AMR through immunization.

• AMR prevention through vaccines                           
• Surveillance and control                               
• Pathogen-resistance mapping                       
• Multidrug-resistant infections

Track 14: Booster Doses and Heterologous Vaccine Regimens     

Booster doses and heterologous vaccine regimens have become critical in strengthening population-wide protection against evolving viral variants. These strategies aim to enhance both the magnitude and durability of immune responses. Heterologous combinations—using different vaccine platforms—have shown promise in improving long-term immunity by stimulating broader cellular and antibody responses. Booster doses help maintain protective levels of immunity as natural defenses wane over time. This approach plays a vital role in managing pandemics and ensuring sustained public health resilience.

• Cross-platform vaccines                             
• Waning immunity                             
• Antibody durability                          
• Post-vaccination monitoring

Track 15: Nanotechnology in Vaccine Delivery

Nanotechnology in Vaccine Delivery has revolutionized the way vaccines are formulated and administered, offering enhanced precision and efficacy. One of the most notable advancements is the use of  lipid nanoparticles, which protect mRNA or antigen payloads and ensure targeted delivery to immune cells. These nanoparticles improve vaccine stability, bioavailability, and reduce degradation during transport in the body. LNP-based delivery played a key role in the success of recent mRNA COVID-19 vaccines. This technology continues to evolve, offering promise for next-generation vaccines against cancer, HIV, and emerging infectious diseases.

• Lipid nanoparticles                           
• Targeted delivery systems                            
• Nano-adjuvants                                 
• Microneedle patches

Track 16: Adjuvants and Immunopotentiators

Adjuvants and Immunopotentiators play a critical role in enhancing the body’s immune response to vaccines. These agents help improve vaccine efficacy by promoting stronger, longer-lasting immunity with smaller antigen doses. New-generation adjuvants are being designed to target specific immune pathways, allowing for tailored responses in different populations. Immunopotentiators are especially vital in developing vaccines for the elderly, immunocompromised, and against complex pathogens. Ongoing research continues to explore safer and more potent combinations to boost vaccine performance globally.

• Alum-based vs novel adjuvants                               
• Cytokine profiling                 
• Safety and potency evaluation

Track 17: Workshops and Poster Sessions

Engage in hands-on workshops led by leading experts in vaccinology, immunotherapy, and biotechnology. These interactive sessions provide practical skills, live demonstrations, and real-time learning opportunities. Participants can also showcase theirwork at our poster sessions or through our ePoster platform, gaining global visibility and feedback. Whether you're sharing novel research, case studies, or pilot trials, this is your chance to make an impact. Collaborate, connect, and inspire innovation through scientific exchange.

• Oral presentation guidelines                         
• Poster design best practices                          
• Young researcher competitions                                
• ePoster virtual tools

Track 18: Corporate Innovation, Sponsorship & Exhibition

Showcase your brand’s impact and thought leadership through a strong exhibitor presence at the Global Mental Health Conference 2026. This is a unique opportunity to engage with leading researchers, policymakers, clinicians, and global mental health advocates. Whether you're launching a product, sharing innovations, or building new networks, your visibility matters. Learn how to become a sponsor or media partner and align your brand with a global cause. Join us in shaping the future of mental health innovation and collaboration.

• Industry-academic collaboration                              
• Product launch at booths                              
• Conference sponsorship plans                                  
• Strategic media partnerships

Benefits of Participation

Join the Global Vaccine Congress 2025

Advancing Immunization Science, Public Health, and Innovation

Participating in the Global Vaccine Congress 2025 offers a unique opportunity for professionals in immunology, virology, public health, biotechnology, and pharmaceutical research to engage with global leaders, present groundbreaking innovations, and foster collaborations. Whether attending in-person or virtually, this international congress is your gateway to cutting-edge insights and professional growth in the vaccine and immunotherapy ecosystem.

Key Benefits for All Participants

• Attend keynote sessions led by world-renowned vaccine scientists, epidemiologists, and public health experts.
• Gain access to all scientific sessions, expert panels, and cross-disciplinary networking opportunities.
• Receive international exposure for your innovations, studies, or public health initiatives.
• Publish your abstract in high-impact journals with exclusive DOI assignment.
• Enjoy publication opportunities and discounts in open-access journals related to vaccines, immunology, and virology.
• Get exclusive access to event handbooks, digital kits, and printed congress materials.
• Collaborate with leaders in vaccine technology, regulatory affairs, global immunization, and infectious diseases.
• Explore latest clinical trials, breakthroughs, and real-world vaccine impact studies.
• Obtain certified recognition for oral and poster presentations.
• Establish global partnerships for research, policy, product development, and academic growth.

Participation Categories:

We welcome a broad spectrum of experts, institutions, and organizations engaged in vaccine science and public health innovation:

• Keynote Speaker: Deliver a 45–50-minute keynote address showcasing your leadership in vaccine research, policy, or delivery systems.
• Speaker (Oral Presentation): Share your original research, clinical results, or public health interventions in a 25–30-minute talk.
• Speaker (Workshop): Host an interactive 45–50-minute workshop on vaccine development, delivery logistics, cold-chain management, or emerging technologies.
• Speaker (Special Session): Collaborate with fellow specialists to lead a focused session on mRNA platforms, global vaccine equity, or regulatory updates.
• Speaker (Symposium): Participate in a 45+ minute multi-speaker symposium exploring topics such as vaccine hesitancy, new delivery systems, or pandemic preparedness.
• Delegate (Registration Only): Attend all sessions, access materials, and benefit from the full conference experience without presenting.
• Poster Presenter: Present your findings in a poster format while enjoying full delegate access and recognition.
• Remote Presenter: Present your research virtually through a live oral or e-poster presentation, with full certification and digital access.
• Exhibitor: Promote your organization, services, or products by securing a booth in the exhibition area—ideal for biotech firms, diagnostics labs, and startups.
• Media Partner / Sponsor / Collaborator: Join forces with Vaccine Congress 2025 for brand exposure, outreach initiatives, and recognition across our global network.

Market Analaysis

Market Analysis: Global Vaccine Market Outlook (2025–2034)

The global vaccine market is poised for substantial growth, reflecting the increasing demand for advanced immunization, public health preparedness, and biotechnology innovation. According to recent projections, the market is expected to grow from USD 91.97 billion in 2025 to an impressive USD 181.99 billion by 2034, demonstrating a compound annual growth rate (CAGR) of over 8.2%.

Key Drivers of Growth:

Increased R&D investments in mRNA, DNA, and vector-based vaccines.

Rising demand for vaccines in emerging economies due to population growth and expanded healthcare coverage.

Government initiatives for universal immunization and pandemic preparedness.

Biotechnological advancements accelerating the discovery and commercialization of new vaccines.

Growing focus on global collaborations, public–private partnerships, and funding initiatives.

Strategic Implications for Stakeholders:

The projected growth of the vaccine market opens vast opportunities for:

Healthcare professionals and researchers to explore new vaccine platforms and therapeutic areas.

Pharmaceutical companies and biotech firmsto expand production, clinical trials, and commercialization strategies.

Public health institutions and policymakers to drive global immunization programs and equitable vaccine access.

Join the Vaccine Revolution at Our Congress!

The Global Vaccine Congress 2025 in Dubai, UAE, brings together world-class experts, organizations, and thought leaders to address this market evolution. Gain firsthand insights into:

• Breakthroughs in vaccine technology
• Global distribution strategies
• Regulatory and funding frameworks
• Industry forecasts and investment trends

Don't miss this opportunity to align your research, business, or public health strategies with the global vaccine market's future trajectory.